Lifecore Biomedical will present at two investor conferences in November 2025, featuring CEO Paul Josephs.
Quiver AI Summary
Lifecore Biomedical, Inc. announced its participation in two investor conferences: the Jefferies 2025 Global Healthcare Conference in London from November 17-20, where CEO Paul Josephs will present on November 18, and the Stephens Annual Investment Conference in Nashville from November 18-20, where he will participate in a fireside chat on November 20. Both events will feature management's involvement in investor meetings and will be available via webcast on Lifecore's investor website. Lifecore is a leading contract development and manufacturing organization specializing in sterile injectable pharmaceutical products and has over 40 years of experience in the biopharmaceutical industry.
Potential Positives
- Lifecore Biomedical's participation in prominent investor conferences enhances its visibility and presents opportunities for networking with potential investors and partners.
- The involvement of the CEO, Paul Josephs, as a speaker at these events reflects confidence and leadership, potentially boosting investor trust in the company's direction.
- Access to webcasts of the presentations allows for a wider audience reach, enabling more investors to engage with the company's strategic initiatives.
Potential Negatives
- None
FAQ
What investor conferences will Lifecore Biomedical participate in?
Lifecore Biomedical will participate in the Jefferies Global Healthcare Conference and Stephens Annual Investment Conference.
Who will represent Lifecore at these conferences?
Paul Josephs, Lifecore’s president and CEO, will deliver presentations and participate in discussions at both conferences.
When will Lifecore’s presentations take place?
Lifecore's presentation at Jefferies is on November 18, 2025, and the fireside chat at Stephens is on November 20, 2025.
How can investors access the conference webcasts?
Webcasts can be accessed via Lifecore’s investor website on the Investor Events & Presentations page.
What products does Lifecore Biomedical specialize in?
Lifecore specializes in sterile injectable pharmaceutical products and is a leading manufacturer of injectable-grade hyaluronic acid.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$LFCR Insider Trading Activity
$LFCR insiders have traded $LFCR stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $LFCR stock by insiders over the last 6 months:
- ARON R. ENGLISH has made 0 purchases and 4 sales selling 1,398,394 shares for an estimated $9,218,855.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$LFCR Hedge Fund Activity
We have seen 44 institutional investors add shares of $LFCR stock to their portfolio, and 41 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- 22NW, LP removed 1,490,981 shares (-84.9%) from their portfolio in Q2 2025, for an estimated $12,106,765
- GRIZZLYROCK CAPITAL, LLC added 734,533 shares (+inf%) to their portfolio in Q2 2025, for an estimated $5,964,407
- INVESCO LTD. added 379,413 shares (+inf%) to their portfolio in Q2 2025, for an estimated $3,080,833
- LANDSCAPE CAPITAL MANAGEMENT, L.L.C. added 136,412 shares (+inf%) to their portfolio in Q2 2025, for an estimated $1,107,665
- STATE STREET CORP added 133,551 shares (+33.6%) to their portfolio in Q2 2025, for an estimated $1,084,434
- BLACKROCK, INC. added 109,907 shares (+6.2%) to their portfolio in Q2 2025, for an estimated $892,444
- ROYAL BANK OF CANADA added 106,855 shares (+610.8%) to their portfolio in Q2 2025, for an estimated $867,662
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$LFCR Analyst Ratings
Wall Street analysts have issued reports on $LFCR in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- William Blair issued a "Outperform" rating on 05/21/2025
To track analyst ratings and price targets for $LFCR, check out Quiver Quantitative's $LFCR forecast page.
Full Release
CHASKA, Minn, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in two upcoming investor conferences. Details regarding Lifecore’s participation are as follows:
-
Jefferies 2025 Global Healthcare Conference – London
Details: Paul Josephs, Lifecore’s president and chief executive officer, will deliver a corporate presentation and Lifecore management will participate in investor meetings
Conference Dates: November 17-20, 2025
Presentation Time/Date: 9:30 – 9:55 a.m. Greenwich Mean Time (4:30 – 4:55 a.m. Eastern Time) on Tuesday, November 18, 2025, webcast available
Location: London, UK
-
Stephens Annual Investment Conference
Details: Mr. Josephs will be a featured speaker in a fireside chat and Lifecore management will participate in 1-on-1 meetings
Conference Dates: November 18-20, 2025
Fireside Chat Time/Date: 9:00 – 9:45 a.m. Central Time on Thursday, November 20, 2025, webcast available
Location: Nashville
Webcasts of the Jefferies presentation and the Stephens fireside chat may be accessed via a link on Lifecore’s investor website on the Investor Events & Presentations page at: https://ir.lifecore.com/events-presentations . Additionally, replays of the webcasts will be available on the Lifecore website following the conference.
About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR ) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com .
